PLSH Company Profile and Key Details

Q: Who are the executives of PLSH?

Dr. James W. Baumgartner Ph.D.Chief Science Officer & Quality ControlMr. Jordan ButtorffChief Information OfficerMr. Nicholas J. CavarraSenior Vice President of Marketing & SalesMr. Nathan Joel BermanSec., Controller & Principal Accounting OfficerMs. Leslie A. ButtorffChairman, Chief Executive Officer & Chief Financial Officer

PNK : PLSH

Panacea Life Sciences

$0.09

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Panacea Life Sciences Holdings, Inc. (PLSH) stock remained unchanged at $0.10 a share on OTC. The stock opened at $0.10, fluctuating between $0.10 to $0.10 during the session.

Stock Snapshot

0.1

Prev. Close

2.12M

Market Cap

0.1

Day Low

17.42

P/E Ratio

0.00574

EPS (TTM)

-0.09

Cash Flow per Share

0.1

Open

21.22M

Number of Shares

0.1

Day High

42.59%

Free Float in %

-0.47

Book Value

10.01K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 11, 2026	0.10	0.10	0.10	0.10	10.01K
Aug 31, 2026	0.10	0.10	0.10	0.10	2.5K
Aug 28, 2026	0.09	0.10	0.09	0.10	13.49K
Aug 21, 2026	0.09	0.09	0.09	0.09	425
Aug 18, 2026	0.08	0.08	0.08	0.08	10K
Aug 14, 2026	0.09	0.09	0.09	0.09	1K
Aug 13, 2026	0.09	0.09	0.09	0.09	137
Aug 11, 2026	0.10	0.10	0.10	0.10	106
Aug 10, 2026	0.10	0.10	0.09	0.09	26.02K
Aug 07, 2026	0.08	0.10	0.08	0.10	11.1K
Aug 06, 2026	0.10	0.10	0.10	0.10	200
Aug 04, 2026	0.08	0.08	0.08	0.08	1K
Jul 30, 2026	0.09	0.09	0.09	0.09	500
Jul 27, 2026	0.10	0.10	0.09	0.09	4.9K
Jul 23, 2026	0.11	0.12	0.08	0.08	1.61K
Jul 20, 2026	0.08	0.12	0.08	0.08	3.98K
Jul 17, 2026	0.12	0.12	0.08	0.08	24.62K
Jul 16, 2026	0.07	0.07	0.07	0.07	13.96K
Jul 14, 2026	0.10	0.10	0.10	0.10	4.4K
Jul 13, 2026	0.10	0.10	0.10	0.10	1.88K

Contact Details

Greenwood Village, CO 80121

United States

https://www.panacealife.com 800 985 0515

About Company

Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products across the entire supply chain, from sourcing to final sale. Its core mission is to develop and deliver natural, pharmaceutical-grade alternatives for both human and pet consumption. The company's diverse product range encompasses items such as softgels, edible gummies, liquid tinctures, sublingual tablets, and a variety of cosmetic and topical applications. In addition to these offerings, the company is involved in the personal protective equipment (PPE) market, importing and distributing hand sanitizers and masks. Panacea Life Sciences also provides white-label and contract manufacturing services to other cannabinoid companies, sells raw materials, and manages tolling arrangements. Established in 2008, the company is headquartered in Greenwood Village, Colorado.

Stock Peers

MKGAF

-6.5-3.38%

MERCK Kommanditgesellschaft auf Aktien$186.00 HKMPY

-0.87-1.69%

Hikma Pharmaceuticals PLC$50.66 SGIOF

Shionogi & Co., Ltd.$43.89 ESALF

Eisai Co., Ltd.$43.00 MKKGY

-0.85-2.24%

MERCK Kommanditgesellschaft auf Aktien$37.11 IPSEY

Ipsen S.A.$33.00 TKPHF

Takeda Pharmaceutical Company Limited$26.83 OCTVV

Octave Intelligence plc$17.48 TEVJF

5.26+43.91%

Teva Pharmaceutical Industries Limited$17.24 APNHY

Aspen Pharmacare Holdings Limited$12.52

Company Overview

The stock is currently mid-range between its 52-week high and low $0.02 and $0.20. With a market capitalization of about $2.12 million, Panacea Life Sciences Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.54). Key stats such as the average daily volume over the past year has been around 15.89 thousand shares, volume is running light vs its 52-week average. Headquartered in Greenwood Village, CO, Panacea Life Sciences Holdings, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Leslie A. Buttorff, the company employs approximately 3 people and listed since April 04, 2022. Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products across the entire supply chain, from sourcing to final sale.

Technical Performance

Average 10-day trading volume of 10.01 thousand shares is below the 3-month average of 29.14 thousand, indicating normal recent market interest.

Valuation Metrics

Panacea Life Sciences Holdings, Inc. trades at a P/E ratio of -0.98, slightly below the S&P 500 average, with a price-to-sales ratio of 8.04 and a price-to-book ratio of 5.41 trading at moderately above to book value. The P/FCF stands at 4.62, also below market averages.

Dividend & Fair Value

Panacea Life Sciences Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Financial & Profitability Overview

Over the trailing twelve months, Panacea Life Sciences generated $2.38M in revenue, or $0.14 per share. Gross margin was 11.13%, operating margin -232.55%, and net profit margin -336.08%. Returns are negative, with ROA at -44.57% and ROE at 96.67%.
On valuation metrics, Panacea Life Sciences trades at a P/E of -0.98, P/S of 8.04 and P/B of 5.41. The current ratio is 2.30 and quick ratio is 0.18. Operationally, the company’s inventory turnover is 3.85 and cash conversion cycle is 86.25 days. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of 2.46.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Panacea Life Sciences posted revenue of $2.38M, down slightly from $1.63M in the prior quarter. Gross profit was $265.49K (margin 11.13%). Operating income was - $5.55M (margin -232.5%). Net income was- $8.02M (EPS - $0.48).
The company ended the quarter with $115.86K in cash and short-term investments, a total debt of $21.65M, and net debt of $21.54M. Total assets were $17.98M, with equity of - $8.29M. Financials further reflected weakness, with operating cash flow of - $1.52M, free cash flow of - $1.59M, and capital expenditures of - $65.32K.

Price Forecast & Outlook

Our AI price prediction model suggests that Panacea Life Sciences Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Panacea Life Sciences Holdings, Inc. trading at a premium to the broader market with a P/E of -0.98.

Frequently Asked Questions

What is the current Panacea Life Sciences Holdings, Inc. (PLSH) stock price?

Panacea Life Sciences Holdings, Inc. (OTC: PLSH) stock price is $0.10 in the last trading session. During the trading session, PLSH stock reached the peak price of $0.10 while $0.10 was the lowest point it dropped to. The percentage change in PLSH stock occurred in the recent session was 0% while the dollar amount for the price change in PLSH stock was $0.00.

PLSH's industry and sector of operation?

The OTC listed PLSH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Panacea Life Sciences Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PLSH?

Dr. James W. Baumgartner Ph.D.
Chief Science Officer & Quality Control
Mr. Jordan Buttorff
Chief Information Officer
Mr. Nicholas J. Cavarra
Senior Vice President of Marketing & Sales
Mr. Nathan Joel Berman
Sec., Controller & Principal Accounting Officer
Ms. Leslie A. Buttorff
Chairman, Chief Executive Officer & Chief Financial Officer

How PLSH did perform over past 52-week?

PLSH's closing price is 0.12% higher than its 52-week low of $0.02 where as its distance from 52-week high of $0.20 is -83.94%.

How many employees does PLSH have?

Number of PLSH employees currently stands at 3.

Link for PLSH official website?

Official Website of PLSH is: https://www.panacealife.com

How do I contact PLSH?

PLSH could be contacted at phone 800 985 0515 and can also be accessed through its website. PLSH operates from 5910 South University Boulevard, Greenwood Village, CO 80121, United States.

How many shares of PLSH are traded daily?

PLSH stock volume for the day was 10.01K shares. The average number of PLSH shares traded daily for last 3 months was 15.89K.

What is the market cap of PLSH currently?

The market value of PLSH currently stands at $2.12M with its latest stock price at $0.10 and 21.22M of its shares outstanding.

Employees	3
Beta	2.54
Sales or Revenue	$2.38M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

PLSH Company Profile and Key Details

Panacea Life Sciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics